Anticancer agent 199

• Description :

  Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine[1].

• CAS Number :

  [2422001-24-7]

• UNSPSC :

  12352005

• Target :

  Apoptosis; Ferroptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/anticancer-agent-199.html

• Solubility :

  10 mM in DMSO

• Smiles :

  OCCN1CCC(CC1)C2CCN(CC2)C3=NC4=C(C(NCC5=CC=C(C(F)=C5)Cl)=N3)N=CN4C6CCCC6

• Molecular Formula :

  C29H39ClFN7O

• Molecular Weight :

  556.12

• References & Citations :

  [1]Sun G, et al. G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis. Bioc

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported